News & Media

Press Releases

Amolyt Pharma Announces Two Presentations, Including Phase 2a Data for AZP-3601 in Patients with Hypoparathyroidism, at the American Society for Bone and Mineral Research 2022 Annual Meeting

September 1, 2022

Download a PDF: EN or FR

Amolyt Pharma Strengthens Leadership Team with Appointment of Mark Sumeray, M.D., as Chief Medical Officer

June 29, 2022

Download a PDF: EN or FR

Amolyt Pharma Announces Positive Results from First Patient Cohort of Phase 2a Trial of AZP-3601 for the Treatment of Hypoparathyroidism

June 1, 2022

Download a PDF: EN or FR

Presentations

AZP-3601

KOL Webinar on AZP-3601 Featuring Professor István Takács

Written by

jpoly4

AZP-3601

Development of the Hypoparathyroidism Daily Diary of Symptom Experience (HPT-DD-SE) and the Hypoparathyroidism Life Impact Questionnaire (HPT-LIQ). ASBMR Poster.

Written by

Dan Hennings

AZP-3601

Living With an “Invisible Disease”: A Qualitative Study With Patients With Hypoparathyroidism

Written by

Dan Hennings

AZP-3813

Sustained Suppression of IGF1 with AZP-3813, a Bicyclic 16-Amino Acid Peptide Antagonist of the Human Growth Hormone Receptor and a Potential New Treatment for Acromegaly. ENDO 2022 Presentation.

Written by

jpoly4

AZP-3813

Sustained Suppression of IGF1 with AZP-3813, a Bicyclic 16-Amino Acid Peptide Antagonist of the Human Growth Hormone Receptor and a Potential New Treatment for Acromegaly. ENDO 2022 Poster.

Written by

jpoly4

AZP-3813

AZP-3813, a Bicyclic 16-Amino Acid Peptide Antagonist of the Human Growth Hormone Receptor as a Potential New Treatment for Acromegaly

Written by

jpoly4

AZP-3601

Healthcare Resource Utilization Burden of Patients with Hypoparathyroidism in the United States

Written by

walid

AZP-3601

KOL Webinar on AZP-3601 Featuring John P. Bilezikian, M.D., Ph.D.

Written by

Olivia

AZP-3601

Clinical Burden of Patients with Hypoparathyroidism in the United States: A Claims Data Analysis. ASMBR 2021.

Written by

walid

AZP-3601

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics following Single and Multiple Administration of AZP-3601, a Novel Long-Acting PTH Analog, to Healthy Adults. ASMBR 2021.

Written by

walid

AZP-3601

Safety, Tolerability and Pharmacodynamics of AZP-3601, a Novel Long-Acting PTH Analog, in Healthy Adults: Data From a Randomized, Double-Blind, Placebo-Controlled Phase 1 Study. e-ECE 2021.

Written by

jpoly4

AZP-3601

cHP Natural History Study: ISPOR Poster

Written by

jpoly4

AZP-3601

A Single Administration of AZP-3601, a Novel, Long-Acting PTH Analog, Induces a Significant and Sustained Calcemic Response: Preliminary Data From a Randomized, Double-Blind, Placebo-Controlled Phase 1 Study. ENDO 2021.

Written by

jpoly4

AZP-3601

Clinical Burden and Practice Patterns in Patients With Chronic Hypoparathyroidism in the United States (US): A Claims Data Analysis Using Diagnosis Based Criteria. ENDO 2021.

Written by

jpoly4

AZP-3601

Clinical Burden and Practice Patterns in Patients With Chronic Hypoparathyroidism in the United States (US): A Claims Data Analysis Using Surgery Based Criteria. ENDO 2021.

Written by

jpoly4

Upcoming events

JPM 2023 41st Annual Healthcare Meeting

Date: January 9-12, 2023 (San Francisco, CA)

Cookie	Duration	Description
cookielawinfo-checkbox-advertisement	1 year	Set by the GDPR Cookie Consent plugin, this cookie is used to record the user consent for the cookies in the "Advertisement" category .
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
elementor	never	This cookie is used by the website's WordPress theme. It allows the website owner to implement or change the website's content in real-time.
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Cookie	Duration	Description
_ga	2 years	The _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors.
_ga_devsite	2 years	This cookie is installed by Google Analytics.
_gid	1 day	Installed by Google Analytics, _gid cookie stores information on how visitors use a website, while also creating an analytics report of the website's performance. Some of the data that are collected include the number of visitors, their source, and the pages they visit anonymously.

News & Media

Press Releases

Amolyt Pharma Announces Two Presentations, Including Phase 2a Data for AZP-3601 in Patients with Hypoparathyroidism, at the American Society for Bone and Mineral Research 2022 Annual Meeting

Amolyt Pharma Strengthens Leadership Team with Appointment of Mark Sumeray, M.D., as Chief Medical Officer

Amolyt Pharma Announces Positive Results from First Patient Cohort of Phase 2a Trial of AZP-3601 for the Treatment of Hypoparathyroidism

Presentations

KOL Webinar on AZP-3601 Featuring Professor István Takács

Development of the Hypoparathyroidism Daily Diary of Symptom Experience (HPT-DD-SE) and the Hypoparathyroidism Life Impact Questionnaire (HPT-LIQ). ASBMR Poster.

Living With an “Invisible Disease”: A Qualitative Study With Patients With Hypoparathyroidism

Sustained Suppression of IGF1 with AZP-3813, a Bicyclic 16-Amino Acid Peptide Antagonist of the Human Growth Hormone Receptor and a Potential New Treatment for Acromegaly. ENDO 2022 Presentation.

Sustained Suppression of IGF1 with AZP-3813, a Bicyclic 16-Amino Acid Peptide Antagonist of the Human Growth Hormone Receptor and a Potential New Treatment for Acromegaly. ENDO 2022 Poster.

AZP-3813, a Bicyclic 16-Amino Acid Peptide Antagonist of the Human Growth Hormone Receptor as a Potential New Treatment for Acromegaly

Healthcare Resource Utilization Burden of Patients with Hypoparathyroidism in the United States

KOL Webinar on AZP-3601 Featuring John P. Bilezikian, M.D., Ph.D.

Clinical Burden of Patients with Hypoparathyroidism in the United States: A Claims Data Analysis. ASMBR 2021.

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics following Single and Multiple Administration of AZP-3601, a Novel Long-Acting PTH Analog, to Healthy Adults. ASMBR 2021.

Safety, Tolerability and Pharmacodynamics of AZP-3601, a Novel Long-Acting PTH Analog, in Healthy Adults: Data From a Randomized, Double-Blind, Placebo-Controlled Phase 1 Study. e-ECE 2021.

cHP Natural History Study: ISPOR Poster

A Single Administration of AZP-3601, a Novel, Long-Acting PTH Analog, Induces a Significant and Sustained Calcemic Response: Preliminary Data From a Randomized, Double-Blind, Placebo-Controlled Phase 1 Study. ENDO 2021.

Clinical Burden and Practice Patterns in Patients With Chronic Hypoparathyroidism in the United States (US): A Claims Data Analysis Using Diagnosis Based Criteria. ENDO 2021.

Clinical Burden and Practice Patterns in Patients With Chronic Hypoparathyroidism in the United States (US): A Claims Data Analysis Using Surgery Based Criteria. ENDO 2021.

Upcoming events

Social Updates

TWITTER